A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor

Myeloid Tumor Clinical Trial

Official title: A Phase Ia/Ib Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor

Status Terminated

Clinical Trial Summary

This is a phase I study evaluating the safety, tolerability and preliminary efficacy of IBI322 in Myeloid tumor patients.

Clinical Trial Description

Phase 1a/1b study will be conducted to evaluate the tolerability, safety, PK, PD, immunogenicity and preliminary antitumor activity of IBI322 in patients with myeloid tumor. Phase 1a is the dose escalation part of the study and Phase 1b is the dose expansion part. Combination therapy with HMA(Azacitidine or Decitabine) will be evaluated. ;

Related Conditions & MeSH terms

• Myeloid Tumor

• NCT number: NCT05148442
• Study type: Interventional
• Source: Innovent Biologics (Suzhou) Co. Ltd.
• Status: Terminated
• Phase: Phase 1
• Start date: December 28, 2021
• Completion date: August 29, 2023